- Home
- COSM
COSM
Cosmos Health Inc.
as 03-28-2025 4:00pm EST
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | THESSALONIKI |
| Market Cap: | 18.4M | IPO Year: | 2013 |
| Target Price: | N/A | AVG Volume (30 days): | 133.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.35 - $1.58 | Next Earning Date: | 11-14-2024 |
| Revenue: | $56,042,109 | Revenue Growth: | 13.02% |
| Revenue Growth (this year): | 4.53% | Revenue Growth (next year): | 25.00% |
Stock Insider Trading Activity of Cosmos Health Inc. (COSM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Siokas Grigorios | COSM | Chief Executive Officer | Mar 4 '25 | Buy | $0.53 | 85,714 | $44,999.85 | 4,115,302 | |
| Siokas Grigorios | COSM | Chief Executive Officer | Mar 3 '25 | Buy | $0.49 | 132,572 | $65,000.05 | 4,115,302 | |
| Siokas Grigorios | COSM | Chief Executive Officer | Feb 24 '25 | Buy | $0.56 | 354,296 | $200,000.09 | 4,115,302 | |
| Siokas Grigorios | COSM | Chief Executive Officer | Jan 30 '25 | Buy | $0.66 | 51,414 | $34,000.08 | 4,115,302 | |
| Siokas Grigorios | COSM | Chief Executive Officer | Jan 22 '25 | Buy | $0.77 | 38,900 | $29,999.68 | 4,115,302 | |
| Siokas Grigorios | COSM | Chief Executive Officer | Jan 17 '25 | Buy | $0.86 | 29,158 | $25,000.07 | 4,115,302 | |
| Siokas Grigorios | COSM | Chief Executive Officer | Jan 16 '25 | Buy | $0.84 | 47,904 | $39,999.84 | 4,115,302 | |
| Siokas Grigorios | COSM | Chief Executive Officer | Jan 15 '25 | Buy | $0.80 | 62,500 | $50,000.00 | 4,115,302 | |
| Siokas Grigorios | COSM | Chief Executive Officer | Jan 14 '25 | Buy | $0.69 | 87,247 | $59,999.76 | 4,115,302 | |
| Siokas Grigorios | COSM | Chief Executive Officer | Jan 13 '25 | Buy | $0.61 | 163,666 | $99,999.93 | 4,115,302 |
Latest Cosmos Health Inc. News
COSM Breaking Stock News: Dive into COSM Ticker-Specific Updates for Smart Investing
Argus Research
11 days ago
Daily – Vickers Top Insider Picks for 03/20/2025
Argus Research
12 days ago
Daily – Vickers Top Insider Picks for 03/19/2025
Argus Research
13 days ago
Daily – Vickers Top Insider Picks for 03/18/2025
Argus Research
14 days ago
Daily – Vickers Top Insider Picks for 03/17/2025
Argus Research
17 days ago
Daily – Vickers Top Insider Picks for 03/14/2025
Argus Research
18 days ago
Daily – Vickers Top Insider Picks for 03/13/2025
Argus Research
19 days ago
Daily – Vickers Top Insider Picks for 03/12/2025
Argus Research
20 days ago
Daily – Vickers Top Insider Picks for 03/11/2025
Compare COSM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COSM Cosmos Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.